CHD Stock Analysis: Church & Dwight | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 23.090m USD | 12M Return: -0.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 183M
EPS Trend: 96.5%
Qual. Beats: 0
Rev. Trend: 93.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Church & Dwight Co., Inc. (NYSE: CHD) is a U.S. consumer staples company that develops, manufactures, and markets household, personal care, and specialty products under three operating segments: Consumer Domestic, Consumer International, and Specialty Products Division. Its portfolio spans well-known brands such as ARM & HAMMER, OXICLEAN, BATISTE, WATERPIK, THERABREATH, TROJAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, and ZICAM, spanning categories from laundry and cleaning to oral care, hair care, and intimate wellness.
In addition to its consumer business, the Specialty Products Division supplies sodium bicarbonate and animal productivity products, including feed additives and probiotics for the dairy, poultry, beef, and swine industries. Consumer products are sold through supermarkets, mass merchandisers, wholesale clubs, drugstores, dollar stores, and e-commerce channels, while specialty products reach industrial customers and livestock producers via distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.
As a large-cap Household Products company within Consumer Staples, Church & Dwight operates in a sector characterized by mature, brand-driven competition against larger multinational peers such as Procter & Gamble, Unilever, Colgate-Palmolive, and Henkel. The companys business model relies on a multi-brand portfolio strategy, using brand extensions and acquisitions to enter adjacent consumer categories while leveraging established distribution relationships across U.S. and international retail channels.
- Premium brand acquisitions expand into high-growth personal care categories
- Commodity input costs pressure household product margins
- Consumer International growth outpaces domestic segment
| Net Income: 733.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.47 > 1.0 |
| NWC/Revenue: 4.95% < 20% (prev 18.96%; Δ -14.00% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.20b > Net Income 733.0m |
| Net Debt (1.87b) to EBITDA (1.29b): 1.45 < 3 |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (238.1m) vs 12m ago -3.99% < -2% |
| Gross Margin: 45.07% > 18% (prev 45.51%; Δ -0.44% > 0.5%) |
| Asset Turnover: 69.09% > 50% (prev 67.79%; Δ 1.31% > 0%) |
| Interest Coverage Ratio: 10.88 > 6 (EBIT TTM 1.04b / Interest Expense TTM 95.9m) |
| A: 0.03 (Total Current Assets 1.72b - Total Current Liabilities 1.41b) / Total Assets 9.01b |
| B: 0.77 (Retained Earnings 6.91b / Total Assets 9.01b) |
| C: 0.12 (EBIT TTM 1.04b / Avg Total Assets 8.98b) |
| D: 0.87 (Book Value of Equity 4.19b / Total Liabilities 4.82b) |
| Altman-Z'' = 4.42 = AA |
| DSRI: 0.94 (Receivables 576.6m/597.5m, Revenue 6.21b/6.07b) |
| GMI: 1.01 (GM 45.51% / 45.07%) |
| AQI: 1.13 (AQ_t 0.72 / AQ_t-1 0.63) |
| SGI: 1.02 (Revenue 6.21b / 6.07b) |
| TATA: -0.05 (NI 733.0m - CFO 1.20b) / TA 9.01b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at USD 96.17 with a total of 2,076,065 shares traded. Over the past week, the price has changed by -0.73%, over one month by +0.86%, over three months by +2.42% and over the past year by -0.62%.
Current recommended Stop Loss: 91.50 (which is 4.9% or 2 ATR below the current price).
Church & Dwight has received a consensus analysts rating of 3.76. Therefore, it is recommended to hold CHD.
- StrongBuy: 8
- Buy: 2
- Hold: 9
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 102.5 | 6.6% |
P/E Trailing = 32.0559
P/E Forward = 26.178
P/S = 3.721
P/B = 5.5811
P/EG = 3.0769
Revenue TTM = 6.21b USD
EBIT TTM = 1.04b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 2.21b USD (from longTermDebt, last quarter)
Short Term Debt = 24.6m USD (from shortTermDebt, last quarter)
Debt = 2.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.87b USD (calculated: Debt 2.38b - CCE 503.4m)
Enterprise Value = 25.0b USD (23.1b + Debt 2.38b - CCE 503.4m)
Interest Coverage Ratio = 10.88 (Ebit TTM 1.04b / Interest Expense TTM 95.9m)
EV/FCF = 23.40x (Enterprise Value 25.0b / FCF TTM 1.07b)
FCF Yield = 4.27% (FCF TTM 1.07b / Enterprise Value 25.0b)
FCF Margin = 17.19% (FCF TTM 1.07b / Revenue TTM 6.21b)
Net Margin = 11.81% (Net Income TTM 733.0m / Revenue TTM 6.21b)
Gross Margin = 45.07% ((Revenue TTM 6.21b - Cost of Revenue TTM 3.41b) / Revenue TTM)
Gross Margin QoQ = 46.38% (prev 45.85%)
Tobins Q-Ratio = 2.77 (Enterprise Value 25.0b / Total Assets 9.01b)
Interest Expense / Debt = 4.03% (Interest Expense 95.9m / Debt 2.38b)
Taxrate = 22.63% (214.4m / 947.4m)
NOPAT = 807.2m (EBIT 1.04b * (1 - 22.63%))
Current Ratio = 1.22 (Total Current Assets 1.72b / Total Current Liabilities 1.41b)
Debt / Equity = 0.57 (Debt 2.38b / totalStockholderEquity, last quarter 4.19b)
Debt / EBITDA = 1.45 (Net Debt 1.87b / EBITDA 1.29b)
Debt / FCF = 1.76 (Net Debt 1.87b / FCF TTM 1.07b)
Total Stockholder Equity = 4.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.16% (Net Income 733.0m / Total Assets 9.01b)
RoE = 17.45% (Net Income TTM 733.0m / Total Stockholder Equity 4.20b)
RoCE = 16.28% (EBIT 1.04b / Capital Employed (Equity 4.20b + L.T.Debt 2.21b))
RoIC = 11.05% (NOPAT 807.2m / Invested Capital 7.31b)
WACC = 5.14% (E(23.1b)/V(25.5b) * Re(5.35%) + D(2.38b)/V(25.5b) * Rd(4.03%) * (1-Tc(0.23)))
Discount Rate = 5.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -31.46 | Cagr: -1.62%
[DCF] Terminal Value 77.95% ; FCFF base≈1.01b ; Y1≈1.16b ; Y5≈1.70b
[DCF] Fair Price = 99.98 (EV 25.6b - Net Debt 1.87b = Equity 23.7b / Shares 236.9m; r=8.35% [WACC [floored]]; 5y FCF grow 14.83% → 2.50% )
EPS Correlation: 96.47 | EPS CAGR: 4.77% | SUE: 0.49 | # QB: 0
Revenue Correlation: 93.62 | Revenue CAGR: 3.08% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.89 | Chg30d=+0.08% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.94 | Chg30d=+0.61% | Revisions=+40% | Analysts=5
EPS current Year (2026-12-31): EPS=3.75 | Chg30d=+0.24% | Revisions=-25% | GrowthEPS=+6.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=4.09 | Chg30d=+2.13% | Revisions=+57% | GrowthEPS=+9.0% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +42% (up=7, down=2)